<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03939702</url>
  </required_header>
  <id_info>
    <org_study_id>CV010-036</org_study_id>
    <nct_id>NCT03939702</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants</brief_title>
  <official_title>Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an ADME study. Human radiolabeled mass balance studies are performed as part of drug
      development to obtain information about the absorption, distribution, metabolism, and
      excretion (ADME) of a study treatment. The goals of human ADME studies include the assessment
      of absorption, distribution, routes and rates of excretion, mass balance, and metabolite
      profile and identification.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2, 2019</start_date>
  <completion_date type="Actual">July 11, 2019</completion_date>
  <primary_completion_date type="Actual">July 11, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess PK Cmax of a dose of [14C]BMS-986177</measure>
    <time_frame>Day 1-12</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess PK AUC(INF) of a dose of [14C]BMS-986177</measure>
    <time_frame>Day 1-12</time_frame>
    <description>AUC(INF)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess PK AUC(0-T) of a dose of [14C]BMS-986177</measure>
    <time_frame>Day 1-12</time_frame>
    <description>AUC(0-T)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess PK Tmax of a dose of [14C]BMS-986177</measure>
    <time_frame>Day 1-12</time_frame>
    <description>Tmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess PK T-HALF of a dose of [14C]BMS-986177</measure>
    <time_frame>Day 1-12</time_frame>
    <description>T-HALF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess PK CL/F of a dose of [14C]BMS-986177</measure>
    <time_frame>Day 1-12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess PK Vz/F of a dose of [14C]BMS-986177</measure>
    <time_frame>Day 1-12</time_frame>
    <description>Vz/F</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess PK AUC of a dose of [14C]BMS-986177</measure>
    <time_frame>Day 1-12</time_frame>
    <description>AUC(BMS-986177)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess PK AUC(TRA) of a dose of [14C]BMS-986177</measure>
    <time_frame>Day 1-12</time_frame>
    <description>AUC(TRA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess PK Plasma AUC(TRA) of a dose of [14C]BMS-986177</measure>
    <time_frame>Day 1-12</time_frame>
    <description>Plasma AUC(TRA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess PK Blood AUC(TRA) of a dose of [14C]BMS-986177</measure>
    <time_frame>Day 1-12</time_frame>
    <description>Blood AUC(TRA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the CLR of [14C]BMS-986177</measure>
    <time_frame>Day 1-12</time_frame>
    <description>CLR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the %UR of [14C]BMS-986177</measure>
    <time_frame>Day 1-12</time_frame>
    <description>%UR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the %FE of [14C]BMS-986177</measure>
    <time_frame>Day 1-12</time_frame>
    <description>%FE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the %BE of [14C]BMS-986177</measure>
    <time_frame>Day 1-12</time_frame>
    <description>%BE (if applicable)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the %Total recovery of [14C]BMS-986177</measure>
    <time_frame>Day 1-12</time_frame>
    <description>%Total recovery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Asess the Incidence of AEs of a single oral dose of 200 mg [14C] BMS-986177</measure>
    <time_frame>Day 1-12</time_frame>
    <description>Incidence of AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asess the Incidence of SAEs of a single oral dose of 200 mg [14C] BMS-986177</measure>
    <time_frame>Day 1-12</time_frame>
    <description>Incidence of SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asess the Incidence of AEs leading to discontinuation of a single oral dose of 200 mg [14C] BMS-986177</measure>
    <time_frame>Day 1-12</time_frame>
    <description>Incidence of AEs leading to discontinuation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the vital signs of a subject dosed with single oral dose of 200 mg [14C] BMS-986177</measure>
    <time_frame>Day 1-12</time_frame>
    <description>results of vital sign examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the ECGs of subjects dosed with single oral dose of 200 mg [14C] BMS-986177</measure>
    <time_frame>Day 1-12</time_frame>
    <description>ECG physical examinations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the clinical lab tests of a single oral dose of 200 mg [14C] BMS-986177</measure>
    <time_frame>Day 1-12</time_frame>
    <description>Results of Clinical laboratory tests</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>Non-Bile Collection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>On Day 1, all participants will receive a single oral solution dose of 200 mg [14C] BMS-986177 containing approximately 88 micro Ci of total radioactivity (TRA). Participants will remain in the clinical facility until at least Day 7 and will be discharged when release criteria are met or until Day 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bile Collection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>On Day 1, all participants will receive a single oral solution dose of 200 mg [14C] BMS-986177 containing approximately 88 micro Ci of total radioactivity (TRA). Approximately 1 hour after study drug administration, an ND tube may be positioned in approximately 3 selected participants for collection of bile.Participants will remain in the clinical facility until at least Day 7 and will be discharged when release criteria are met or until Day 12</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986177</intervention_name>
    <description>An orally administered anticoagulant to prevent and treat thromboembolic events</description>
    <arm_group_label>Bile Collection</arm_group_label>
    <arm_group_label>Non-Bile Collection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed ICF

          -  Healthy Male

          -  Body mass index of 18.0 to 32.0 kg/m2, inclusive.

          -  Agreement to use approved contraception for 94 days post treatment

          -  Agreement to not donate sperm for 94 days post treatment

        Exclusion Criteria:

          -  Acute or chronic illness

          -  GI disease current or recent

          -  History of dizziness or recurring headaches

          -  Head injury within last 2 years

          -  GI surgery

          -  History or evidence of abnormal bleeding
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Born male</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Covance Clinical Research Unit, Inc.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 2, 2019</study_first_submitted>
  <study_first_submitted_qc>May 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

